GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,378.50GBp
18 Dec 2014
Price Change (% chg)

31.50p (+2.34%)
Prev Close
1,347.00p
Open
1,354.00p
Day's High
1,380.50p
Day's Low
1,335.50p
Volume
13,091,726
Avg. Vol
9,847,690
52-wk High
1,709.00p
52-wk Low
1,296.50p

GSK.L

Chart for GSK.L

About

GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. GSK’s principal pharmaceutical products include medicines in... (more)

Overall

Beta: 0.55
Market Cap (Mil.): £65,509.10
Shares Outstanding (Mil.): 4,863.33
Dividend: 19.00
Yield (%): 5.94

Financials

  GSK.L Industry Sector
P/E (TTM): 15.70 36.60 37.24
EPS (TTM): 0.86 -- --
ROI: 16.65 18.95 18.21
ROE: 75.96 19.73 19.11
Search Stocks

UPDATE 1-New GSK shingles vaccine may challenge Merck after strong test data

* GSK vaccine cuts risk of shingles by 97.2 pct in over 50s

11:00am EST

GSK shareholders approve asset swap deal with Novartis

LONDON, Dec 18 - Shareholders in British drugmaker GlaxoSmithKline have approved a planned deal with Switzerland's Novartis, which will see the two pharmaceutical groups trade more than $20 billion of assets.

8:11am EST

GlaxoSmithKline shingles vaccine hits goal in major study

LONDON, Dec 18 - An experimental vaccine against shingles from GlaxoSmithKline met its goal in a late-stage study, in a boost for the company's vaccine unit, which is expanding part of its overall healthcare business.

7:42am EST

Fitch Affirms GlaxoSmithKline PLC at 'A+'; Revises Outlook to Negative

(The following statement was released by the rating agency) LONDON, December 17 (Fitch) Fitch Ratings has affirmed UK-based pharmaceuticals company GlaxoSmithKline PLC's (GSK) Long-term Issuer Default Rating (IDR) and senior unsecured rating at 'A+'. The Outlook has been revised to Negative from Stable. Fitch has also affirmed the senior unsecured rating of 'A+' for the debt issued under GlaxoSmithKline Capital PLC. The Negative Outlook encapsulates Fitch's expectation of increasing financia

17 Dec 2014

Antibiotic developer Cempra's CEO says not looking for a buyer

- Cempra Inc has no plans for now to sell itself, its CEO said, brushing off talk that the company is a potential target as big drugmakers set their sights on antibiotic developers.

12 Dec 2014

BRIEF-GSK files regulatory submission for variation to marketing authorisation for Ambrisentan

* GSK press release: GSK announces EU regulatory submission seeking extended indication for Ambrisentan (Volibris) in pulmonary arterial hypertension

11 Dec 2014

One shot or two? Many questions unresolved in Ebola vaccine race

* Debate over "prime-boost" vaccination as epidemic evolves

11 Dec 2014

BRIEF-Aspen Pharmacare director Abbas Hussain resigns

* Abbas Hussain has confirmed that he intends to tender his resignation as a director of company with effect from Feb. 1 2015

10 Dec 2014

Merck to take on superbugs with Cubist Pharma buy

- Merck & Co Inc said it would buy Cubist Pharmaceuticals Inc for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that combat so-called superbugs.

08 Dec 2014

UPDATE 4-Merck to take on superbugs with Cubist Pharma buy

* Merck to pay $8.4 bln, plus assumption of $1.1 bln of debt

08 Dec 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$125.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks